Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner

• Main Authors: Cancan Zheng (Author), Xiaomei Yu (Author), Yiyao Liang (Author), Yidong Zhu (Author), Yan He (Author), Long Liao (Author), Dingkang Wang (Author), Yanming Yang (Author), Xingfeng Yin (Author), Ang Li (Author), Qingyu He (Author), Bin Li (Author)
• Format: Book
• Published: Elsevier, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

As one of the hallmarks of cancer, metabolic reprogramming leads to cancer progression, and targeting glycolytic enzymes could be useful strategies for cancer therapy. By screening a small molecule library consisting of 1320 FDA-approved drugs, we found that penfluridol, an antipsychotic drug used t...